HupA, Huperzina A, Huperzine, Huperzine-A, Selagine, Sélagine.
Huperzine A is a substance purified from a plant called Chinese club moss. Although the makers of huperzine A start with a plant, their product is the result of a lot of laboratory manipulation. It is a highly purified drug, unlike herbs that typically contain hundreds of chemical ingredients. As a result, some people regard huperzine A as a drug, and they argue that it stretches the guidelines of the Dietary Supplement Health and Education Act (DSHEA).
Be careful not to confuse huperzine A, which is also called selagine, with similar sounding medications such as selegiline (Eldepryl). Also be careful not to confuse one of the brand names for huperizine A (Cerebra) with the brand names for unrelated prescription drugs such as celecoxib (Celebrex), citalopram (Celexa), and fosphenytoin (Cerebyx).
Huperzine A is used for Alzheimer's disease, memory and learning enhancement, and age-related memory impairment. It is also used for treating a muscle disease called myasthenia gravis, for increasing alertness and energy, and for protecting against agents that damage the nerves such as nerve gases.
Products that combine huperzine A with certain drugs used for treating Alzheimer's disease are being studied. These “hybrid” products are of interest because they may be effective at lower doses and, therefore, cause fewer side effects. One hybrid, called huprine X, combines huperzine A with the drug donepezil. Another hybrid being studied contains huperzine A and the drug tacrine.
How does it work?
Huperzine A is thought to be beneficial for problems with memory, loss of mental abilities (dementia), and the muscular disorder myasthenia gravis because it causes an increase in the levels of acetylcholine. Acetylcholine is one of the chemicals that our nerves use to communicate in the brain, muscles, and other areas.
Possibly Effective for...
- Dementia. Some research suggests that taking huperzine A by mouth for up to 8 weeks may improve memory, mental function, and behavior in people with conditions such as Alzheimer's disease or dementia. The long-term effects of huperizine A in people with these conditions is not yet known.
- Memory. Some research shows that taking huperzine A by mouth for 4 weeks improves the memory older children and teenagers who complain of memory problems.
Insufficient Evidence to Rate Effectiveness for...
- Mental impairment. Early research suggests that taking huperzine A by mouth for 12 weeks might improve memory in adults with mild cognitive (mental) impairment.
- A muscular disorder called myasthenia gravis. Early research suggests that giving huperzine A intramuscularly for 10 days may prevent muscle weakness in patients with myasthenia gravis and may have equal or longer lasting effects compared to intramuscular neostigmine.
- Age-related memory loss.
- Increasing alertness and energy.
- Protection from agents poisonous to nerves.
- Other conditions.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Huperzine A is POSSIBLY SAFE when taken by mouth for a short period of time (less than 3 months). It can cause some side effects including nausea, diarrhea, vomiting, sweating, blurred vision, slurred speech, restlessness, loss of appetite, contraction and twitching of muscle fibers, cramping, increased saliva and urine, inability to control urination, high blood pressure, and slowed heart rate.
Slow heart rate or other heart diseases: Huperzine A can slow the heart rate. This might be a problem for people who already have a slow heart rate or other heart conditions involving the heart rate. If you have heart disease, use huperzine A cautiously.
Gastrointestinal (GI) tract blockage: There is a concern that using huperzine A might make GI blockage worse. That is because huperzine A can increase mucous and fluid secretions in the intestine, causing “congestion.” If you have a GI tract blockage, check with your healthcare provider before you use huperzine A.
Sores in the stomach or the first part of the small intestine (peptic ulcers): There is a concern that using huperzine A might make peptic ulcers worse. That is because huperzine A can increase mucous and fluid secretions in the stomach and intestine, causing “congestion.” If you have peptic ulcers, check with your healthcare provider before you use huperzine A.
Lung conditions such as asthma or emphysema: There is a concern that using huperzine A might make asthma or emphysema worse. That is because huperzine A can increase mucous and fluid secretions in the lung, causing “congestion.” If you have asthma or emphysema, check with your healthcare provider before you use huperzine A.
Urinary tract or reproductive system blockage: There is a concern that using huperzine A might make blockage of the urinary or reproductive system worse. That is because huperzine A can increase mucous and fluid secretions in these organs, causing “congestion.” If you have a urinary tract or reproductive system blockage, check with your healthcare provider before you use huperzine A.
Drying medications (Anticholinergic drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Huperzine A contains chemicals that can affect the brain and heart. Some of these drying medications called anticholinergic drugs can also affect the brain and heart. But huperzine A works differently than drying medications. Huperzine A might decrease the effects of drying medications.
Some of these drying medications include atropine, benztropine (Cogentin), biperiden (Akineton), procyclidine (Kemadrin), scopolamine, trihexyphenidyl (Artane), and some medications used for allergies (antihistamines), and for depression (antidepressants).
Medications for Alzheimer's disease (Acetylcholinesterase (AChE) inhibitors)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Huperzine A contains a chemical that affects the brain. Medications for Alzheimer's disease also affect the brain. Taking Huperzine A along with medications for Alzheimer's disease might increase effects and side effects of medications for Alzheimer's disease.
Some of these medications include donepezil (Aricept), echothiophate (Phospholine Iodide), edrophonium (Enlon, Reversol, Tensilon), neostigmine (Prostigmin), physostigmine (Antilirium), pyridostigmine (Mestinon, Regonol), and tacrine (Cognex).
Various medications used for glaucoma, Alzheimer's disease, and other conditions (Cholinergic drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Huperzine A contains a chemical that affects the body. This chemical is similar to some medications used for glaucoma, Alzheimer's disease and other conditions. Taking Huperzine A with these medications might increase the chance of side effects.
Some of these medications used for glaucoma, Alzheimer's disease, and other conditions include pilocarpine (Pilocar and others), donepezil (Aricept), tacrine (Cognex), and others.
The following doses have been studied in scientific research:
- For Alzheimer's disease and declining thinking skills due to changes in the blood vessels in the brain (vascular dementia; also known as multi-infarct dementia): Doses of 50-200 mcg of Huperzine A twice daily.
- For age-related decline in thinking skills (senile or presenile dementia): Doses of 30 mcg twice daily.
- For improving memory in adolescents: Doses of 100 mcg twice daily.
- For prevention of muscle weakness caused by a disease called myasthenia gravis: Healthcare providers give Huperzine A daily as a shot.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Aisen, P. A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function. Georgetown University Medical Center, Memory Disorders Program 2004;
Alcala, Mdel M., Vivas, N. M., Hospital, S., Camps, P., Munoz-Torrero, D., and Badia, A. Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids. Neuropharmacology 2003;44(6):749-755. View abstract.
Ariel, N., Ordentlich, A., Barak, D., Bino, T., Velan, B., and Shafferman, A. The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem J 10-1-1998;335 ( Pt 1):95-102. View abstract.
Ashani, Y., Grunwald, J., Kronman, C., Velan, B., and Shafferman, A. Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase. Mol.Pharmacol 1994;45(3):555-560. View abstract.
Ashani, Y., Peggins, J. O., III, and Doctor, B. P. Mechanism of inhibition of cholinesterases by huperzine A. Biochem Biophys.Res.Commun. 4-30-1992;184(2):719-726. View abstract.
Babot, Z., Cristofol, R., and Sunol, C. Excitotoxic death induced by released glutamate in depolarized primary cultures of mouse cerebellar granule cells is dependent on GABAA receptors and niflumic acid-sensitive chloride channels. Eur J Neurosci. 2005;21(1):103-112. View abstract.
Bai, D. L., Tang, X. C., and He, X. C. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr.Med Chem 2000;7(3):355-374. View abstract.
Brouillet, E. and Beal, M. F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport 1993;4(4):387-390. View abstract.
Camps, P. and Munoz-Torrero, D. Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Mini.Rev Med Chem 2001;1(2):163-174. View abstract.
Camps, P., El, Achab R., Morral, J., Munoz-Torrero, D., Badia, A., Banos, J. E., Vivas, N. M., Barril, X., Orozco, M., and Luque, F. J. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem 11-30-2000;43(24):4657-4666. View abstract.
Camps, P., Gomez, E., Munoz-Torrero, D., Badia, A., Clos, M. V., Curutchet, C., Munoz-Muriedas, J., and Luque, F. J. Binding of 13-amidohuprines to acetylcholinesterase: exploring the ligand-induced conformational change of the gly117-gly118 peptide bond in the oxyanion hole. J Med Chem 11-16-2006;49(23):6833-6840. View abstract.
Chen M, Gao Z, Deng H, and et al. Huperzine A capsules vs tablets in treatment of Alzheimer disease: multicenter studies. Chinese Journal of New Drugs and Clinical Remedies 2000;19(1):10-12.
Cheng YS, Lu CZ, Ying ZL, and et al. [128 cases of myasthenia gravis treated with huperzine A]. New Drugs Clin Remedies 1986;5(4):197-199.
Cheng, D. H., Ren, H., and Tang, X. C. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 12-20-1996;8(1):97-101. View abstract.
Chow, T. W. Review: insufficient evidence on Huperzine A for Alzheimer's. Evid Based Ment.Health 2008;11(4):112. View abstract.
Chu, D. F., Fu, X. Q., Liu, W. H., Liu, K., and Li, Y. X. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm 11-15-2006;325(1-2):116-123. View abstract.
Chu, D., Liu, W., Li, Y., Li, P., Gu, J., and Liu, K. Pharmacokinetics of huperzine A in dogs following single intravenous and oral administrations. Planta Med 2006;72(6):552-555. View abstract.
Costagli, C. and Galli, A. Inhibition of cholinesterase-associated aryl acylamidase activity by anticholinesterase agents: focus on drugs potentially effective in Alzheimer's disease. Biochem Pharmacol 5-15-1998;55(10):1733-1737. View abstract.
Darrouzain, F., Andre, C., Ismaili, L., Matoga, M., and Guillaume, Y. C. Huperzine A--human serum albumin association: chromatographic and thermodynamic approach. J Chromatogr.B Analyt.Technol Biomed.Life Sci 6-25-2005;820(2):283-288. View abstract.
Darvesh, S., MacDonald, S. E., Losier, A. M., Martin, E., Hopkins, D. A., and Armour, J. A. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. J Auton.Nerv Syst. 7-15-1998;71(2-3):75-84. View abstract.
Darvesh, S., Walsh, R., and Martin, E. Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases. Cell Mol.Neurobiol. 2003;23(1):93-100. View abstract.
Diamond, B., Johnson, S., Torsney, K., Morodan, J., Prokop, B., Davidek, D., and Kramer, P. Complementary and alternative medicines in the treatment of dementia: an evidence-based review. Drugs Aging 2003;20(13):981-998. View abstract.
Dong, W. X., Gu, F. H., Li, P. Y., and Tao, T. Pharmacodynamics of in situ gel and tablets of huperzine A in impaired memory mice and rats. Chinese Journal of Pharmaceuticals 2006;37:101-104.
Doraiswamy, P. M. and Xiong, G. L. Pharmacological strategies for the prevention of Alzheimer's disease. Expert.Opin.Pharmacother. 2006;7(1):1-10. View abstract.
Du ZM, Li SL, and Yang CF. [A randomised study of huperzine: a therapy on senile amnestic syndrome]. Chinese Journal of Geriatrics 1996;15(3):180.
Du, D. M. and Carlier, P. R. Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. Curr Pharm Des 2004;10(25):3141-3156. View abstract.
Duysen, E. G., Li, B., Darvesh, S., and Lockridge, O. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 4-20-2007;233(1-3):60-69. View abstract.
Eckert, S., Eyer, P., and Worek, F. Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 4-20-2007;233(1-3):180-186. View abstract.
Eckert, S., Eyer, P., Muckter, H., and Worek, F. Kinetic analysis of the protection afforded by reversible inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus compounds. Biochem Pharmacol 7-28-2006;72(3):344-357. View abstract.
Fayuk, D. and Yakel, J. L. Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol.Pharmacol 2004;66(3):658-666. View abstract.
Filliat, P., Foquin, A., and Lallement, G. Effects of chronic administration of huperzine A on memory in guinea pigs. Drug Chem Toxicol 2002;25(1):9-24. View abstract.
Finkelstein, B. L., Benner, E. A., Hendrixson, M. C., Kranis, K. T., Rauh, J. J., Sethuraman, M. R., and McCann, S. F. Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors. Bioorg.Med Chem 2002;10(3):599-613. View abstract.
Fu, X. D., Gao, Y. L., Ping, Q. N., and Ren, T. Preparation and in vivo evaluation of huperzine A-loaded PLGA microspheres. Arch Pharm Res 2005;28(9):1092-1096. View abstract.
Galeotti, N. Antinociceptive profile of the natural cholinesterase inhibitor huperzine A. Drug Development Research 2001;54:19.
Gao, P., Xu, H., Ding, P., Gao, Q., Sun, J., and Chen, D. Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies. Int J Pharm 2-7-2007;330(1-2):1-5. View abstract.
Geib, S. J., Tuckmantel, W., and Kozikowski, A. P. Huperzine A--a potent acetylcholinesterase inhibitor of use in the treatment of Alzheimer's disease. Acta Crystallogr.C. 4-15-1991;47 ( Pt 4):824-827. View abstract.
Gemma, S., Gabellieri, E., Huleatt, P., Fattorusso, C., Borriello, M., Catalanotti, B., Butini, S., De, Angelis M., Novellino, E., Nacci, V., Belinskaya, T., Saxena, A., and Campiani, G. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J Med Chem 6-1-2006;49(11):3421-3425. View abstract.
Gordon, R. K., Nigam, S. V., Weitz, J. A., Dave, J. R., Doctor, B. P., and Ved, H. S. The NMDA receptor ion channel: a site for binding of Huperzine A. J Appl Toxicol 2001;21 Suppl 1:S47-S51. View abstract.
Haigh, J. R., Johnston, S. R., Peppernay, A., Mattern, P. J., Garcia, G. E., Doctor, B. P., Gordon, R. K., and Aisen, P. S. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact. 9-25-2008;175(1-3):380-386. View abstract.
Hameda, A. B., Elosta, S., and Havel, J. Optimization of the capillary zone electrophoresis method for Huperzine A determination using experimental design and artificial neural networks. J Chromatogr.A 8-19-2005;1084(1-2):7-12. View abstract.
Hanin, I., Tang, X. C., Kindel, G. L., and Kozikowski, A. P. Natural and synthetic Huperzine A: effect on cholinergic function in vitro and in vivo. Ann N Y Acad Sci 9-24-1993;695:304-306. View abstract.
Hao, Z., Liu, M., Liu, Z., and Lv, D. Huperzine A for vascular dementia. Cochrane Database Syst.Rev 2009;(2):CD007365. View abstract.
Houghton, P. J. and Howes, M. J. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals. 2005;14(1-2):6-22. View abstract.
Huperzine A. Drugs R.D. 2004;5(1):44-45. View abstract.
Jiang, H., Luo, X., and Bai, D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease. Curr Med Chem 2003;10(21):2231-2252. View abstract.
Jin, G., Luo, X., He, X., Jiang, H., Zhang, H., and Bai, D. Synthesis and docking studies of alkylene-linked dimers of (-)-huperzine A. Arzneimittelforschung 2003;53(11):753-757. View abstract.
Kaplan, D., Ordentlich, A., Barak, D., Ariel, N., Kronman, C., Velan, B., and Shafferman, A. Does "butyrylization" of acetylcholinesterase through substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase? Biochemistry 6-26-2001;40(25):7433-7445. View abstract.
Kaur, J. and Zhang, M. Q. Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors. Curr Med Chem 2000;7(3):273-294. View abstract.
Kuang, M. Clinical evaluation of huperzine A in improving interlligent disorder in patients with Alzheimer's disease. Zhongguo Linchuang Kangfu 2004;8(7):1216.
Laganiere, S., Corey, J., Tang, X. C., Wulfert, E., and Hanin, I. Acute and chronic studies with the anticholinesterase Huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology 1991;30(7):763-768. View abstract.
Lallement, G. [Pretreatment of organophosphate poisoning: potential interests of huperzine A]. Ann Pharm Fr. 2000;58(1):13-17. View abstract.
Lallement, G., Baille, V., Baubichon, D., Carpentier, P., Collombet, J. M., Filliat, P., Foquin, A., Four, E., Masqueliez, C., Testylier, G., Tonduli, L., and Dorandeu, F. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 2002;23(1):1-5. View abstract.
Li, J., Han, Y. Y., and Liu JS. Studies on alkaloids of Qiancengta (Huperzia serrata). Chinese Traditional and Herbal Drugs 1987;18:50.
Li, J., Wu, H. M., Zhou, R. L., Liu, G. J., and Dong, B. R. Huperzine A for Alzheimer's disease. Cochrane Database Syst.Rev 2008;(2):CD005592. View abstract.
Li, K. Change of thyroid function in patients with Alzheimer disease after treatment of huperzine A. Zhongguo Linchuang Kangfu 2006;10(22):70.
Li, W. M., Kan, K. K., Carlier, P. R., Pang, Y. P., and Han, Y. F. East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A. Curr Alzheimer Res 2007;4(4):386-396. View abstract.
Li, W., Li, J., and Hu, Q. Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. Biomed.Chromatogr. 2008;22(4):354-360. View abstract.
Li, Y. and Hu, G. Y. Huperzine A inhibits the sustained potassium current in rat dissociated hippocampal neurons. Neurosci.Lett 8-30-2002;329(2):153-156. View abstract.
Li, Y. and Hu, G. Y. Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons. Neurosci.Lett 5-10-2002;324(1):25-28. View abstract.
Li, Y. X., Jiang, X. H., Lan, K., and Wang, L. Simple determination of huperzine A in human plasma by liquid chromatographic-tandem mass spectrometric method. Biomed.Chromatogr. 2007;21(1):15-20. View abstract.
Li, Y. X., Zhang, R. Q., Li, C. R., and Jiang, X. H. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet. 2007;32(4):183-187. View abstract.
Little, J. T., Walsh, S., and Aisen, P. S. An update on huperzine A as a treatment for Alzheimer's disease. Expert.Opin.Investig.Drugs 2008;17(2):209-215. View abstract.
Liu FG, Fang YS, Gao ZX, and et al. [Double-blind randomised controlled trial of huperzine-A in 28 patients with Alzheimer disease]. Journal of Pharmacoepidemiology 1995;4(4):196-198.
Liu, W. H., Song, J. L., Liu, K., Chu, D. F., and Li, Y. X. Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer's disease. J Control Release 10-20-2005;107(3):417-427. View abstract.
Lv, PY., Song, CF., Fan, JF., Yin, Y., and Liang, CP. The effect of huperzine A on N-methyl-D-aspartate receptor in neuron of hippocampus in mice with vascular dementia by immunohistochemistry and in situ hybridization. Chinese Journal of Hospital Pharmacy 2005;25:NIL.
Ma, X. C., Wang, H. X., Xin, J., Zhang, T., and Tu, Z. H. Effects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin. 2003;24(8):831-835. View abstract.
Ma, X. C., Xin, J., Wang, H. X., Zhang, T., and Tu, Z. H. Acute effects of huperzine A and tacrine on rat liver. Acta Pharmacol Sin. 2003;24(3):247-250. View abstract.
Ma, X., Tan, C., Zhu, D., and Gang, D. R. A survey of potential huperzine A natural resources in China: the Huperziaceae. J Ethnopharmacol. 3-8-2006;104(1-2):54-67. View abstract.
Ma, X., Tan, C., Zhu, D., and Gang, D. R. Is there a better source of huperzine A than Huperzia serrata? Huperzine A content of Huperziaceae species in China. J Agric.Food Chem 3-9-2005;53(5):1393-1398. View abstract.
Mazurek A. An open label trial of huperzine A in the treatment of Alzheimer's disease. Altern Ther 1999;5(2):97-98.
McKinney, M., Miller, J. H., Yamada, F., Tuckmantel, W., and Kozikowski, A. P. Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur J Pharmacol 10-15-1991;203(2):303-305. View abstract.
Naik, R. S., Doctor, B. P., and Saxena, A. Comparison of methods used for the determination of cholinesterase activity in whole blood. Chem Biol Interact. 9-25-2008;175(1-3):298-302. View abstract.
Pang, Y. P. and Kozikowski, A. P. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program. J Comput.Aided Mol.Des 1994;8(6):683-693. View abstract.
Patil, K. D., Buerki, R. A., and Patil, P. N. Potentiation of acetylcholine action by huperzine-A and physostigmine on some vertebrate effectors, including human iris sphincter muscle. J Ocul.Pharmacol Ther 2003;19(2):135-143. View abstract.
Patocka, J. Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine. Acta Medica (Hradec.Kralove) 1998;41(4):155-157. View abstract.
Peng, Y., Jiang, L., Lee, D. Y., Schachter, S. C., Ma, Z., and Lemere, C. A. Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells. J Neurosci.Res 2006;84(4):903-911. View abstract.
Peng, Y., Lee, D. Y., Jiang, L., Ma, Z., Schachter, S. C., and Lemere, C. A. Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. Neuroscience 12-5-2007;150(2):386-395. View abstract.
Pepping, J. Huperzine A. Am J Health Syst Pharm 3-15-2000;57(6):530, 533-534. View abstract.
Pilotaz, F. and Masson, P. [Huperzine a: an acetylcholinesterase inhibitor with high pharmacological potential]. Ann Pharm Fr. 1999;57(5):363-373. View abstract.
Qian, B. C., Wang, M., Zhou, Z. F., Chen, K., Zhou, R. R., and Chen, G. S. Pharmacokinetics of tablet huperzine A in six volunteers. Zhongguo Yao Li Xue.Bao. 1995;16(5):396-398. View abstract.
Rajendran, V., Prakash, K. R., Ved, H. S., Saxena, A., Doctor, B. P., and Kozikowski, A. P. Synthesis, chiral chromatographic separation, and biological activities of the enantiomers of 10,10-dimethylhuperzine A. Bioorg.Med Chem Lett 11-6-2000;10(21):2467-2469. View abstract.
Ricordel, I. and Meunier, J. [Chemical weapons: antidotes. View about the real means, perspectives]. Ann Pharm Fr. 2000;58(1):5-12. View abstract.
Saxena, A., Qian, N., Kovach, I. M., Kozikowski, A. P., Pang, Y. P., Vellom, D. C., Radic, Z., Quinn, D., Taylor, P., and Doctor, B. P. Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases. Protein Sci 1994;3(10):1770-1778. View abstract.
Saxena, A., Redman, A. M., Jiang, X., Lockridge, O., and Doctor, B. P. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 12-2-1997;36(48):14642-14651. View abstract.
Saxena, A., Redman, A. M., Jiang, X., Lockridge, O., and Doctor, B. P. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Chem Biol Interact. 5-14-1999;119-120:61-69. View abstract.
Shafferman, A., Barak, D., Stein, D., Kronman, C., Velan, B., Greig, N. H., and Ordentlich, A. Flexibility versus "rigidity" of the functional architecture of AChE active center. Chem Biol Interact. 9-25-2008;175(1-3):166-172. View abstract.
Skolnick, A. A. Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA 3-12-1997;277(10):776. View abstract.
Szegletes, T., Mallender, W. D., and Rosenberry, T. L. Nonequilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands. Biochemistry 3-24-1998;37(12):4206-4216. View abstract.
Tan, C. H., Chen, G. F., Ma, X. Q., Jiang, S. H., and Zhu, D. Y. Three new phlegmariurine B type lycopodium alkaloids from Huperzia serrata. J Asian Nat.Prod Res 2002;4(3):227-231. View abstract.
Tan, C. H., Ma, X. Q., Chen, G. F., and Zhu, D. Y. Huperzines S, T, and U: New Lycopodium alkaloids from Huperzia serrata. Canadian Journal of Chemistry 2003;81(4):315.
Tang XC and Han YF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. Cns Drug Reviews 1999;5(3):281-300.
Tang, L. L., Wang, R., and Tang, X. C. Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production. Eur J Pharmacol 9-5-2005;519(1-2):9-15. View abstract.
Tang, X. C. Huperzine A (shuangyiping): a promising drug for Alzheimer's disease. Zhongguo Yao Li Xue.Bao.(Acta Pharmacologica Sinica) 1996;17(6):481-484. View abstract.
Tang, X. C., Kindel, G. H., Kozikowski, A. P., and Hanin, I. Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol. 1994;44(3):147-155. View abstract.
Tao, T., Zhao, Y., Yue, P., Dong, W. X., and Chen, Q. H. [Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration]. Yao Xue Xue Bao 2006;41(11):1104-1110. View abstract.
Tonduli, L. S., Testylier, G., Masqueliez, C., Lallement, G., and Monmaur, P. Effects of Huperzine used as pre-treatment against soman-induced seizures. Neurotoxicology 2001;22(1):29-37. View abstract.
Ved, H. S., Koenig, M. L., Dave, J. R., and Doctor, B. P. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 3-3-1997;8(4):963-968. View abstract.
Wang, G., Zhang, S. Q., and Zhan, H. [Effect of huperzine A on cerebral cholinesterase and acetylcholine in elderly patients during recovery from general anesthesia]. Nan Fang Yi Ke Da Xue Xue Bao 2006;26(11):1660-1662. View abstract.
Wang, L. M., Han, Y. F., and Tang, X. C. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 6-9-2000;398(1):65-72. View abstract.
Wang, L. S., Zhou, J., Shao, X. M., and Tang, X. C. [Huperzine A attenuates cognitive deficits and brain injury after hypoxia-ischemic brain damage in neonatal rats]. Zhonghua Er.Ke Za Zhi 2003;41(1):42-45. View abstract.
Wang, L. S., Zhou, J., Shao, X. M., and Tang, X. C. Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res 9-13-2002;949(1-2):162-170. View abstract.
Wang, R. and Tang, X. C. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals. 2005;14(1-2):71-82. View abstract.
Wang, R., Xiao, X. Q., and Tang, X. C. Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Neuroreport 8-28-2001;12(12):2629-2634. View abstract.
Wang, R., Yan, H., and Tang, X. C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27(1):1-26. View abstract.
Wang, R., Zhang, H. Y., and Tang, X. C. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur.J Pharmacol 6-15-2001;421(3):149-156. View abstract.
Wang, W. Effect of huperzine A on memory function of patients with mild cognitive impairment. Zhongguo Linchuang Kangfu 2005;9(8):23.
Wang, X. D., Chen, X. Q., Yang, H. H., and Hu, G. Y. Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex. Neurosci.Lett 9-3-1999;272(1):21-24. View abstract.
Wang, Z, Ren, G, Zhao, Y, and et al. A double-blind study of huperzine A and piracetam in patients with age-associated memory impairment and dementia. Herbal Medicines for Neuropsychiatric Diseases 1999;39-50.
Wang, Z. F. and Tang, X. C. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett 2-20-2007;581(4):596-602. View abstract.
Wang, Z. F., Wang, J., Zhang, H. Y., and Tang, X. C. Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem. 2008;106(4):1594-1603. View abstract.
Wu, Q. and Gu, Y. Quantification of huperzine A in Huperzia serrata by HPLC-UV and identification of the major constituents in its alkaloid extracts by HPLC-DAD-MS-MS. J Pharm Biomed.Anal 3-3-2006;40(4):993-998. View abstract.
Wu, ZM., Bai, M., and Ding, PT. Pharmacokinetic properties of huperzine A sustained release tablets. Chinese Journal of New Drugs 2008;17:36-39.
Xiao, X. Q., Wang, R., Han, Y. F., and Tang, X. C. Protective effects of huperzine A on beta-amyloid(25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci.Lett 6-9-2000;286(3):155-158. View abstract.
Xiao, X. Q., Yang, J. W., and Tang, X. C. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci.Lett 11-12-1999;275(2):73-76. View abstract.
Xiao, X. Q., Zhang, H. Y., and Tang, X. C. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci.Res 1-1-2002;67(1):30-36. View abstract.
Xiong, Z. Q. and Tang, X. C. Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav 1995;51(2-3):415-419. View abstract.
Xu SS, Gao ZX, Weng Z, and et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Int Med J 1997;4(2):127-131.
Xu, Y., Shen, J., Luo, X., Silman, I., Sussman, J. L., Chen, K., and Jiang, H. How does huperzine A enter and leave the binding gorge of acetylcholinesterase? Steered molecular dynamics simulations. J Am Chem Soc 9-17-2003;125(37):11340-11349. View abstract.
Xue, SW., Ding, JM., Zhong, P., Liang, K., An, HY., and Bo, Y. Impacts of huperzine A on the level of Fas, Apo2.7 and Bcl-2 on the platelet membrane and the cognitive function in patients with Alzheimer disease. Zhongguo Linchuang Kangfu 2005;9(9):188.
Yan, H. and Tang, X. C. Review on clinical application of huperzine A in China. Chinese Journal of New Drugs and Clinical Remedies 2006;25:682.
Yan, H., Zhang, H. Y., and Tang, X. C. Involvement of M1-muscarinic acetylcholine receptors, protein kinase C and mitogen-activated protein kinase in the effect of huperzine A on secretory amyloid precursor protein-alpha. Neuroreport 5-7-2007;18(7):689-692. View abstract.
Yang, C. Efficacy and reliability of huperzine a in mild and moderate alzheimer's disease. Zhongguo Linchuang Kangfu 2003;7(31):4258.
Ye, J. C., Zeng, S., Zheng, G. L., and Chen, G. S. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm 5-22-2008;356(1-2):187-192. View abstract.
Ye, J. W., Shang, Y. Z., Wang, Z. M., and Tang, X. C. Huperzine A ameliorates the impaired memory of aged rat in the Morris water maze performance. Acta Pharmacol Sin. 2000;21(1):65-69. View abstract.
Yuan, S. Q. and Zhao, Y. M. [A novel phlegmariurine type alkaloid from Huperzia serrata (Thunb.) Trev]. Yao Xue Xue Bao 2003;38(8):596-598. View abstract.
Yuan, S. Q., Feng, R., and Gu, G. M. Studies on the alkaloids of shezushishan (Huperzia serrata). Chinese Traditional and Herbal Drugs 1994;25:453.
Yuan, S. Q., Feng, R., and Gu, G. M. Studies on the alkaloids of shezushishan (Huperzia serrata). Chinese Traditional and Herbal Drugs 1995;26:115.
Yue, P., Tao, T., Zhao, Y., Ren, J., and Chai, X. Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharm 6-7-2007;337(1-2):127-132. View abstract.
Zangara, A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Behav 2003;75(3):675-686. View abstract.
Zhang, G. B., Wang, M. Y., Zheng, J. Q., and Tang, X. C. [Facilitation of cholinergic transmission by huperzine A in toad paravertebral ganglia in vitro]. Zhongguo Yao Li Xue.Bao. 1994;15(2):158-161. View abstract.
Zhang, H. Y. and Tang, X. C. Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons. Neurosci.Lett 4-10-2003;340(2):91-94. View abstract.
Zhang, H. Y., Liang, Y. Q., Tang, X. C., He, X. C., and Bai, D. L. Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci.Lett 1-14-2002;317(3):143-146. View abstract.
Zhang, H. Y., Yan, H., and Tang, X. C. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci.Lett 4-22-2004;360(1-2):21-24. View abstract.
Zhang, J. M. and Hu, G. Y. Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons. Neuroscience 2001;105(3):663-669. View abstract.
Zhang, M. Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer's disease. Journal of New Drugs and Clinical Remedies 2006;25:693.
Zhang, Y. H., Chen, X. Q., Yang, H. H., Jin, G. Y., Bai, D. L., and Hu, G. Y. Similar potency of the enantiomers of huperzine A in inhibition of [(3)H]dizocilpine (MK-801) binding in rat cerebral cortex. Neurosci.Lett 12-8-2000;295(3):116-118. View abstract.
Zhang, Y. H., Zhao, X. Y., Chen, X. Q., Wang, Y., Yang, H. H., and Hu, G. Y. Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex. Neurosci.Lett 2-15-2002;319(2):107-110. View abstract.
Zhang, Z. J., Tong, Y., Wang, X. Y., Yao, S. M., Jin, G. X., and Wang, X. P. Huperzine A as add-on therapy in patients with treatment-resistant schizophrenia: an open-labeled trial. Schizophr.Res 2007;92(1-3):273-275. View abstract.
Zhang, Z., Wang, X., Chen, Q., Shu, L., Wang, J., and Shan, G. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi Xue Za Zhi 7-25-2002;82(14):941-944. View abstract.
Zhao, H. W. and Li, X. Y. Ginkgolide A, B, and huperzine A inhibit nitric oxide production from rat C6 and human BT325 glioma cells. Zhongguo Yao Li Xue Bao 1999;20(10):941-943. View abstract.
Zhao, H. W. and Li, X. Y. Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity. Int Immunopharmacol. 2002;2(11):1551-1556. View abstract.
Zhou, H., Li, Y. S., Tong, X. T., Liu, H. Q., Jiang, S. H., and Zhu, D. Y. Serratane-type triterpenoids from Huperzia serrata. Nat.Prod Res 2004;18(5):453-459. View abstract.
Zhou, J. and Tang, X. C. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett 8-28-2002;526(1-3):21-25. View abstract.
Zhou, J., Fu, Y., and Tang, X. C. Huperzine A protects rat pheochromocytoma cells against oxygen-glucose deprivation. Neuroreport 7-20-2001;12(10):2073-2077. View abstract.
Zhou, J., Zhang, H. Y., and Tang, X. C. Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci.Lett 11-9-2001;313(3):137-140. View abstract.
Zhu, X. Z. Development of natural products as drugs acting on central nervous system. Mem.Inst.Oswaldo Cruz 1991;86 Suppl 2:173-175. View abstract.
Zhu, X. Z., Li, X. Y., and Liu, J. Recent pharmacological studies on natural products in China. Eur J Pharmacol 10-1-2004;500(1-3):221-230. View abstract.
Camps P, Cusack B, Mallender WD, et al. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000;57:409-17. View abstract.
Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998;60:377-86. View abstract.
Cheng YS, Lu CZ, Ying ZL, et al. [128 cases of myasthenia gravis treated with huperzine A]. New Drugs and Clinical Remedies 1986;5:197-9.
Felgenhauer N, Zilker T, Worek F, Eyer P. Intoxication with huperzine A, a potent anticholinesterase found in the fir club moss. J Toxicol Clin Toxicol 2000;38:803-8.. View abstract.
Grunwald J, Raveh L, Doctor BP, Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 1994;54:991-7. View abstract.
Lallement G, Veyret J, Masqueliez C, et al. Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality. Fundam Clin Pharmacol 1997;11:387-94. View abstract.
Pepping J. Huperzine A. Am J Health Syst Pharm 2000;57:530-4.
Safety Briefs, ISMP Medication Safety Alert, vol.4, #4. Institute for Safe Medication Practices, Warminster, PA. February 24, 1999.
Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer Disease therapy. JAMA 1997;277:776.
Sun QQ, Xu SS, Pan JL, et al. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Chung Kuo Yao Li Hsueh Pao 1999;20:601-3. View abstract.
Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989;24:276-85. View abstract.
Wang H, Tang XC. Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Chung Kuo Yao Li Hsueh Pao 1998;19:27-30. View abstract.
Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 1998;349:137-42. View abstract.
Wang XD, Zhang JM, Yang HH, Hu GY. Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Chung Kuo Yao Li Hsueh Pao 1999;20:31-5. View abstract.
Xiong ZQ, Cheng DH, Tang XC. Effects of huperzine A on nucleus basalis magnocellularis lesion-induced spatial working memory deficit. Chung Kuo Yao Li Hsueh Pao 1998;19:128-32. View abstract.
Xu SS, Cai ZY, Qu ZW, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999;20:486-90. View abstract.
Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao 1995;16:391-5. View abstract.
Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther 1999;288:814-9.. View abstract.
Zhang RW, Tang XC, Han YY, et al. [Drug evaluation of huperzine A in the treatment of senile memory disorders]. Chung Kuo Yao Li Hsueh Pao 1991;12:250-2. View abstract.
Zhang SL. [Therapeutic effects of huperzine A on the aged with memory impairment]. New Drugs and Clinical Remedies 1986;5:260-2.